Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics

References

• Hellström PM, Benno P. The Rome IV: irritable bowel syndrome – a functional disorder. Best Pract Res Clin Gastroenterol. 2019;40–41:101634.
   PubMed Web of Science ®Google Scholar
• Hellström PM. Pathophysiology of the irritable bowel syndrome – reflections of today. Best Pract Res Clin Gastroenterol. 2019;40–41:101620.
   PubMed Web of Science ®Google Scholar
• Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150(6):1262–1279.e2.
   Web of Science ®Google Scholar
• Mosińska P, Salaga M, Fichna J. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. Expert Opin Investig Drugs. 2016;25(3):275–286.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chang L, Schneck S, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532–1541.
   PubMed Web of Science ®Google Scholar
• Hellström PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther. 2009;29(2):198–206.
   PubMed Web of Science ®Google Scholar
• Farzaei MH, Bahramsoltani R, Abdollahi M, et al. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558–574.
   PubMed Web of Science ®Google Scholar
• O'Malley D. Neuroimmune cross talk in the gut. Neuroendocrine and neuroimmune pathways contribute to the pathophysiology of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2016;311(5):G934–G941.
   PubMed Web of Science ®Google Scholar
• Benno P, Norin E, Midtvedt T, et al. Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS. Best Pract Res Clin Gastroenterol. 2019;40–41:101607.
   PubMed Web of Science ®Google Scholar
• Myneedu K, Deoker A, Schmulson MJ, et al. Fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis. United European Gastroenterol J. 2019;7(8):1033–1041.
   PubMed Web of Science ®Google Scholar
• Schoenfeld PS. Advances in IBS 2016: a review of current and emerging data. Gastroenterol Hepatol. 2016;12(8 Suppl. 3):1–11.
   Google Scholar
• Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, et al. Irritable bowel syndrome – from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(1):1–9.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Weiser K, Lee RD. The treatment of irritable bowel syndrome. Ther Adv Gastroenterol. 2009;2(4):221–238.
   PubMedGoogle Scholar
• Hellström PM. GLP-1: broadening the incretin concept to involve gut motility. Regul Pept. 2009;156(1–3):9–12.
   PubMedGoogle Scholar
• Hellström PM. Glucagon-like peptide-1 gastrointestinal regulatory role in metabolism and motility. Vitam Horm. 2010;84:319–329.
   PubMed Web of Science ®Google Scholar
• Hellström PM. GLP-1 playing the role of a gut regulatory compound. Acta Physiol. 2011;201(1):151–156.
   PubMed Web of Science ®Google Scholar
• Halim MA, Degerblad M, Sundbom M, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab. 2018;103(2):575–585.
   PubMed Web of Science ®Google Scholar
• Rowlands J, Heng J, Newsholme P, et al. Pleiotropic effects of GLP-1 and analogs on cell signaling. Front Endocrinol. 2018;9(672):672.
   PubMedGoogle Scholar
• Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166(1):27–41.
   PubMed Web of Science ®Google Scholar
• Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.
   PubMed Web of Science ®Google Scholar
• Graaf C, Donnelly D, Wootten D, et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68(4):954–1013.
   PubMed Web of Science ®Google Scholar
• Knauf C, Abot A, Wemelle E, et al. Targeting the enteric nervous system to treat metabolic disorders? "Enterosynes" as therapeutic gut factors. Neuroendocrinology. 2020;110(1–2):139–146.
   PubMed Web of Science ®Google Scholar
• Trapp S, Richards JE. The gut hormone glucagon-like peptide-1 produced in brain: is this physiologically relevant? Curr Opin Pharmacol. 2013;13(6):964–969.
   PubMed Web of Science ®Google Scholar
• Hellström PM, Naslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008;20(6):649–659.
   PubMed Web of Science ®Google Scholar
• Li Z-Y, Zhang N, Wen S, et al. Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2017;41(4):459–465.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(1):G120–G128.
   PubMed Web of Science ®Google Scholar
• Yang Y, Cui X, Chen Y, et al. Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity. J Physiol Pharmacol. 2014;65(3):349–357.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim N. Sex-gender differences in irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24(4):544–558.
   PubMed Web of Science ®Google Scholar
• O'Brien R, O'Malley D. The glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of irritable bowel syndrome. Neurogastroenterol Motil. 2020;32(2):e13738.
   PubMed Web of Science ®Google Scholar
• Siekmeier R, Hofmann T, Scheuch G, et al. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome. Adv Exp Med Biol. 2015;849:23–38.
   PubMed Web of Science ®Google Scholar
• Lindberg G. Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. Best Pract Res Clin Gastroenterol. 2019;40–41:101635.
   PubMed Web of Science ®Google Scholar
• Wongtrakul W, Charoenngam N, Ungprasert P. Increased prevalence of irritable bowel syndrome in migraine patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2021;34(1):56–63.
   Google Scholar
• Mertsalmi TH, But A, Pekkonen E, et al. Irritable bowel syndrome and risk of Parkinson's disease in Finland: a nationwide registry-based cohort study. J Parkinsons Dis. 2021;11(2):641–651.
   PubMedGoogle Scholar
• Yoon SY, Shin J, Heo SJ, et al. Irritable bowel syndrome and subsequent risk of Parkinson's disease: a nationwide population-based matched-cohort study. J Neurol. 2021.
   Google Scholar
• Zweig A, Schindler V, Becker AS, et al. Higher prevalence of joint hypermobility in constipation predominant irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(9):e13353.
   PubMed Web of Science ®Google Scholar
• Halawi H, Camilleri M, Acosta A, et al. Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. Am J Physiol Gastrointest Liver Physiol. 2017;313(5):G442–G447.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Crowley MJ, Gislum M, et al. Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER Subgroup Analyses. Diabetes Ther. 2021;12(4):1099–1116.
   PubMed Web of Science ®Google Scholar
• Almario CV, Eberlein S, Khalil C, et al. Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome. Neurogastroenterol Motil. 2021;33:e14145.
   PubMed Web of Science ®Google Scholar
• Salehi M, Aulinger B, Prigeon RL, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. 2010;59(6):1330–1337.
   PubMed Web of Science ®Google Scholar
• Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13(5):444–450.
   PubMedGoogle Scholar
• Wijkman MO, Dena M, Dahlqvist S, et al. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. J Clin Hypertens. 2019;21(1):105–115.
   Web of Science ®Google Scholar